Enliven Therapeutics (ELVN) Cash & Equivalents (2019 - 2026)

Enliven Therapeutics has disclosed Cash & Equivalents across 8 years of filings, most recently posting $132.2 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $132.2 million, up 29.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $132.2 million (up 29.97% YoY), and the FY2025 annual result was $98.9 million, down 20.32% from the prior year.
• Cash & Equivalents came in at $132.2 million for Q1 2026 at Enliven Therapeutics, up from $98.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $292.1 million in Q1 2023 to a low of $73.8 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $100.6 million (2024), against an average of $115.9 million.
• Across the five-year window, Cash & Equivalents surged 192.46% in 2023 and tumbled 48.93% in 2024, its largest moves.
• Enliven Therapeutics' Cash & Equivalents stood at $75.5 million in 2022, then soared by 32.57% to $100.1 million in 2023, then grew by 23.94% to $124.1 million in 2024, then declined by 20.32% to $98.9 million in 2025, then surged by 33.66% to $132.2 million in 2026.
• The last three Cash & Equivalents figures came in at $132.2 million (Q1 2026), $98.9 million (Q4 2025), and $101.7 million (Q3 2025), per Business Quant data.